Gilead Sciences, Inc (GILD) concluded trading on Wednesday at a closing price of $113.56, with 5.22 million shares of worth about $592.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.16% during that period and on July 23, 2025 the price saw a gain of about 3.08%. Currently the company’s common shares owned by public are about 1.25B shares, out of which, 1.24B shares are available for trading.
Stock saw a price change of 3.38% in past 5 days and over the past one month there was a price change of 6.94%. Year-to-date (YTD), GILD shares are showing a performance of 56.50% which increased to 22.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $70.78 but also hit the highest price of $119.96 during that period. The average intraday trading volume for Gilead Sciences, Inc shares is 8.18 million. The stock is currently trading 2.75% above its 20-day simple moving average (SMA20), while that difference is up 4.26% for SMA50 and it goes to 12.67% higher than SMA200.
Gilead Sciences, Inc (NASDAQ: GILD) currently have 1.25B outstanding shares and institutions hold larger chunk of about 86.99% of that.
The stock has a current market capitalization of $141.26B and its 3Y-monthly beta is at 0.35. PE ratio of stock for trailing 12 months is 23.88, while it has posted earnings per share of $4.76 in the same period. Its PEG reads 0.91 and has Quick Ratio of 1.23 while making debt-to-equity ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GILD, volatility over the week remained 2.37% while standing at 2.21% over the month.
Stock’s fiscal year EPS is expected to rise by 73.07% while it is estimated to increase by 7.03% in next year. EPS is likely to grow at an annualized rate of 26.21% for next 5-years, compared to annual growth of -38.13% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on April 22, 2025 offering an Overweight rating for the stock and assigned a target price of $125 to it. Coverage by Oppenheimer stated Gilead Sciences, Inc (GILD) stock as an Outperform in their note to investors on March 04, 2025, suggesting a price target of $132 for the stock. On February 18, 2025, Deutsche Bank Upgrade their recommendations, while on February 13, 2025, DZ Bank Upgrade their ratings for the stock with a price target of $108. Stock get an Overweight rating from Morgan Stanley on January 10, 2025.
